logo-loader
viewCytoDyn Inc.

CytoDyn to showcase leronlimab's HIV-prevention potential at Boston medical conference

A recent study showed leronlimab preventing intrarectal transmission of Simian-Human Immunodeficiency Virus in macaques

Medical staff seated in a circle at case meeting
Leronlimab, unlike current PrEP HIV-prevention treatments, only needs to be taken once a month

CytoDyn Inc (OTCMKTS:CYDY) announced that an abstract on the potential of its drug candidate leronlimab for the prevention of HIV has been accepted for presentation at the Conference on Retroviruses and Opportunistic Infections (CROI) in Boston.  

The presentation will detail results from a recent study that show leronlimab preventing intrarectal transmission of Simian-Human Immunodeficiency Virus (SHIV) in macaques. 

Jonah Sacha, a professor at the Vaccine and Gene Therapy Institute at the Oregon Health & Science University and a senior adviser to CytoDyn, will lead the presentation. 

READ: CytoDyn brings on Yahoo!, Shutterfly veteran law expert

“The acceptance of Dr. Sacha’s late-breaking abstract describing leronlimab’s utility in HIV prevention underscores the potential of leronlimab for treatments beyond suppression of established HIV infection,” CEO Nader Pourhassan said in a statement. “Leronlimab could offer a much needed, simple and long-lasting preventative treatment option for people at risk of HIV infection. The results from this study are extremely promising and further support our efforts to begin clinical trials for leronlimab as a PrEP treatment.”

One problem with current pre-exposure prophylaxis (PrEP) treatments, is the necessity of a daily regimen, Pourhassan said, which makes long-term treatment difficult.

Leronlimab, on the other hand, only needs to be taken monthly. 

“The eradication of HIV could get a boost with the use of leronlimab as a once monthly 700 mg injection to prevent HIV,” Pourhassan said. “This could be a powerful paradigm shift in the world of HIV prevention.”

The presentation, titled “CCR5 antibody blockade protects macaques from intrarectal SHIV acquisition,” will take place at 2:30 pm ET on March 9 at the Hynes Convention Center in Boston.

CytoDyn, based in Vancouver, Washington, is also currently working with the Thai Red Cross AIDS Research Centre to conduct a PrEP clinical trial examining leronlimab in people at high risk of HIV infection.

In addition to its potential as a prevention mechanism, leronlimab has earned Fast Track status from the US Food and Drug administration for two other possible uses: a part of a combination therapy for HIV-infected patients and a treatment for metastatic triple-negative breast cancer.

Contact Andrew Kessel at [email protected] 

Follow him on Twitter @andrew_kessel

Quick facts: CytoDyn Inc.

Price: 1.095 USD

OTCMKTS:CYDY
Market: OTCQB
Market Cap: $471.68 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of CytoDyn Inc. named herein, including the promotion by the Company of CytoDyn Inc. in any Content on the Site, the Company receives from said...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Full interview: CytoDyn forms partnership with Chinese medical services...

CytoDyn Inc (OTCMKTS:CYDY) CEO Nader Pourhassan tells Proactive the biopharma has signed a nonbinding letter of intent with Chinese medical services provider Longen China Group to develop and license its drug leronlimab as a treatment for coronavirus. Pourhassan says its important the...

1 week, 5 days ago

2 min read